Lomaira
Caloric Restriction, Obesity, Type 2 Diabetes + 6 more
Treatment
3 FDA approvals
20 Active Studies for Lomaira
Treatment for
Caloric Restriction
What is Lomaira
Phentermine
The Generic name of this drug
Treatment Summary
Phentermine is an appetite suppressant that was approved as a part of an anti-obesity combination drug in 1959. It is related to amphetamine, but is classified as a Schedule IV drug due to its low risk of addiction. Phentermine is used in the short-term to manage weight and was approved alone or in combination with the drug topiramate in 2012.
Ionamin
is the brand name
Lomaira Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ionamin
Phentermine
1959
298
Approved as Treatment by the FDA
Phentermine, also known as Ionamin, is approved by the FDA for 3 uses including Obesity and Comorbidity .
Obesity
Used to treat Obesity in combination with Topiramate
Comorbidity
Used to treat one related comorbidity in combination with Topiramate
Regime of weight reduction
Effectiveness
How Lomaira Affects Patients
Phentermine is thought to reduce appetite, possibly by increasing levels of the hormone leptin. It may also increase how much energy you burn at rest. People taking phentermine in clinical studies typically lost an average of 3.6 kg (about 8 pounds) over 2-24 weeks. After stopping taking phentermine, people were able to maintain this weight loss. Unlike some other medications related to amphetamines, phentermine does not cause central nervous system stimulation, high blood pressure, decreased effectiveness with long-term use, or changes in heart rhythm.
How Lomaira works in the body
Phentermine works by releasing adrenaline in the brain, which stimulates the body to be on alert and reduces hunger signals. It also affects serotonin, dopamine, and norepinephrine levels, and weakly inhibits monoamine oxidase. Overall, this creates a state of alertness and reduces the feeling of hunger.
When to interrupt dosage
The measure of Lomaira is reliant upon the diagnosed situation, including Regime of weight reduction, Hyperlipidemia and Type 2 Diabetes. The dose fluctuates as per the technique of delivery (e.g. Oral or Tablet) featured in the table underneath.
Condition
Dosage
Administration
Obesity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Caloric Restriction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Type 2 Diabetes
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Hypertensive disease
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
High Cholesterol
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Regime of weight reduction
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Chronic Weight Management therapy
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
increase in physical activity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Comorbidity
, 30.0 mg, 15.0 mg, 37.5 mg, 3.75 mg, 7.5 mg, 11.25 mg, 8.0 mg, 18.8 mg
Oral, , Capsule, Capsule - Oral, Capsule, extended release - Oral, Capsule, extended release, Tablet - Oral, Tablet, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Warnings
Lomaira Contraindications
Condition
Risk Level
Notes
Hyperthyroidism
Do Not Combine
concomitant use or 14 days after discontinuation
Do Not Combine
Agitation
Do Not Combine
Drug abuse
Do Not Combine
Cardiovascular Diseases
Do Not Combine
Open-angle glaucoma
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Phentermine may interact with Pulse Frequency
There are 20 known major drug interactions with Lomaira.
Common Lomaira Drug Interactions
Drug Name
Risk Level
Description
Iobenguane
Major
Phentermine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blue
Major
Phentermine may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Phentermine may increase the serotonergic activities of Mirtazapine.
1-benzylimidazole
Minor
The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Phentermine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Phentermine is combined with 4-Methoxyamphetamine.
Lomaira Toxicity & Overdose Risk
In rats, the toxic dose of phentermine is 151mg/kg. Symptoms of overdose can include restlessness, shaking, overactive reflexes, fast breathing, confusion, aggression, hallucinations, and panic followed by fatigue and depression. It can also affect the cardiovascular system with rapid heart rate, abnormal heart rhythms, high or low blood pressure, and circulation failure. In the digestive system, it can cause nausea, vomiting, diarrhea, and stomach cramps. Treatment for acute overdose includes supportive care and stomach pumping with sedation with barbiturates. Chronic overdosing can lead to skin problems, difficulty sleeping, irritability, hyper
Lomaira Novel Uses: Which Conditions Have a Clinical Trial Featuring Lomaira?
104 active studies are currently investigating the potential of Lomaira to combat Type 2 Diabetes, facilitate Weight Reduction and treat Disease.
Condition
Clinical Trials
Trial Phases
Type 2 Diabetes
89 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Obesity
0 Actively Recruiting
Hypertensive disease
0 Actively Recruiting
Comorbidity
0 Actively Recruiting
High Cholesterol
18 Actively Recruiting
Phase 2, Phase 3, Early Phase 1, Not Applicable
Caloric Restriction
0 Actively Recruiting
Regime of weight reduction
0 Actively Recruiting
increase in physical activity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Lomaira Reviews: What are patients saying about Lomaira?
5
Patient Review
9/27/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
10/12/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
10/6/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
8/2/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
7/23/2020
Lomaira for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
5
Patient Review
7/16/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
7/9/2020
Lomaira for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
5
Patient Review
12/4/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
8/9/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
9/5/2020
Lomaira for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
5
Patient Review
9/14/2020
Lomaira for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
5
Patient Review
11/16/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
10/27/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
11/28/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
8/25/2020
Lomaira for Weight Loss Management for an Obese Person
5
Patient Review
8/18/2020
Lomaira for Weight Loss Management for Overweight Person with BMI 27 to 29 and Weight-Related Comorbidity
5
Patient Review
9/20/2020
Lomaira for Weight Loss Management for an Obese Person
Patient Q&A Section about lomaira
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How long can I stay on Lomaira?
"Lomaira can be used for short-term use, for up to 12 weeks."
Answered by AI
What are the side effects of Lomaira?
"You may experience some of the following side effects: dizziness, dry mouth, difficulty sleeping, irritability, nausea, vomiting, diarrhea, or constipation. If you notice any of these effects lasting or getting worse, tell your doctor or pharmacist."
Answered by AI
Is Lomaira as good as phentermine?
"The lowest strength of phentermine that is approved to be used three times a day is LOMAIRA. The37.5 mg dose of generic phentermine is the highest dose and is taken once a day before breakfast."
Answered by AI
Does Lomaira help you lose weight?
"Lomaira may help you lose weight if used for three months as part of a diet and exercise routine. Patients may pay 50¢ per tablet for the duration of treatment."
Answered by AI